ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view
ImmunityBio shares rose about 1% to $8.70 premarket after reporting ANKTIVA net product revenue of $113 million for 2025, up roughly 700% from 2024. The company posted a $351.4 million net loss and ended the year with $242.8 million in cash. ANKTIVA is now authorized in 33 countries, including recent European approval. Traders are watching cash burn and upcoming regulatory milestones.